Chapter 485: Global Issues in Medicine¶
Global Medicine PART 17
KEY CLINICAL POINTS¶
- Global health equity requires equitable access to high-value health interventions, emphasizing the integration of prevention and care.
- The Global Burden of Disease (GBD) study highlights that noncommunicable diseases (NCDs) now account for 74% of global deaths, surpassing communicable diseases.
- HIV/AIDS, tuberculosis, and malaria remain major burdens, with significant disparities in treatment access and outcomes between high- and low-income countries.
1. DEFINITION & OVERVIEW¶
Global health is the field of study and practice focused on improving health outcomes and achieving health equity worldwide, addressing transnational health problems. It emphasizes the role of international collaboration, resource allocation, and systemic approaches to health care delivery.
Table 485-1: Leading Causes of Burden of Disease (DALYs), 2019¶
| DISEASE OR INJURY | DALYS (MILLIONS) | PERCENTAGE OF TOTAL DALYs |
|---|---|---|
| Neonatal disorders | 185.9 | 7.3 |
| Ischemic heart disease | 182.0 | 7.2 |
| Stroke | 143.2 | 5.7 |
| Lower respiratory infection | 97.2 | 3.8 |
| Diarrheal diseases | 80.9 | 3.2 |
| COPD | 74.4 | 2.9 |
| Road injuries | 72.9 | 2.9 |
| Diabetes | 70.9 | 2.8 |
| Low back pain | 63.7 | 2.5 |
| Congenital defects | 52.8 | 2.1 |
1.1 Historical Context¶
Global health emerged as a distinct field in the 1970s, with the Alma-Ata Declaration (1978) promoting 'Health for All by the Year 2000.' Key institutions like the World Health Organization (WHO) and the World Bank have shaped global health priorities, though challenges persist in coordination and funding.
1.2 Key Challenges¶
Persistent disparities in health outcomes, resource allocation, and access to care. The rise of noncommunicable diseases (NCDs) and the ongoing impact of infectious diseases like HIV/AIDS, tuberculosis, and malaria underscore the complexity of global health.
2. EPIDEMIOLOGY¶
Global health disparities are stark, with low-income countries bearing the brunt of disease burden. In 2019, 74% of global deaths were attributed to NCDs, while communicable diseases, maternal, and neonatal conditions accounted for 26%. Poverty remains a critical determinant of health outcomes.
Table 485-2: Leading Causes of Death Worldwide, 2019¶
| DISEASE OR INJURY | DEATHS (MILLIONS) | PERCENTAGE OF TOTAL DEATHS |
|---|---|---|
| Ischemic heart disease | 9.1 | 16.1 |
| Stroke | 6.6 | 11.7 |
| COPD | 3.3 | 5.8 |
| Lower respiratory infection | 2.5 | 4.4 |
| Lung cancer | 2.0 | 3.6 |
| Neonatal disorders | 1.9 | 3.3 |
| Alzheimer’s disease | 1.6 | 2.9 |
| Diabetes | 1.6 | 2.7 |
| Diarrheal diseases | 1.5 | 2.7 |
| Cirrhosis | 1.5 | 2.6 |
2.1 Mortality Trends¶
In 2019, ischemic heart disease (9.1 million deaths) and stroke (6.6 million) were leading causes of death. Neonatal disorders (1.9 million) and lower respiratory infections (2.5 million) also contributed significantly. NCDs now dominate global mortality, reflecting shifts in disease burden.
2.2 Regional Disparities¶
Sub-Saharan Africa and South Asia account for 95% of malaria deaths and 80% of HIV infections. Low-income countries face higher burdens of infectious diseases, while NCDs are increasingly prevalent in middle-income regions.
3. ETIOLOGY & PATHOPHYSIOLOGY¶
Disease burden is driven by both communicable and noncommunicable factors. Environmental risks (e.g., indoor air pollution, poor sanitation) contribute to 25% of DALYs from lower respiratory infections. NCDs like ischemic heart disease and diabetes are linked to lifestyle, genetics, and socioeconomic factors.
Table 485-1: Leading Causes of Burden of Disease (DALYs), 2019¶
| DISEASE OR INJURY | DALYS (MILLIONS) | PERCENTAGE OF TOTAL DALYs |
|---|---|---|
| Neonatal disorders | 185.9 | 7.3 |
| Ischemic heart disease | 182.0 | 7.2 |
| DISEASE OR INJURY | DALYS (MILLIONS) | PERCENTAGE OF TOTAL DALYs |
|---|---|---|
| Stroke | 143.2 | 5.7 |
| Lower respiratory infection | 97.2 | 3.8 |
| Diarrheal diseases | 80.9 | 3.2 |
| COPD | 74.4 | 2.9 |
| Road injuries | 72.9 | 2.9 |
| Diabetes | 70.9 | 2.8 |
| Low back pain | 63.7 | 2.5 |
| Congenital defects | 52.8 | 2.1 |
3.1 Communicable Diseases¶
HIV/AIDS, tuberculosis, and malaria remain major global health threats. HIV co-infection exacerbates tuberculosis, while drug-resistant strains (MDR-TB, XDR-TB) complicate treatment. Malaria disproportionately affects children in low-income regions.
3.2 Noncommunicable Diseases¶
NCDs are driven by modifiable risk factors like tobacco use, poor diet, and sedentary lifestyles. Cardiovascular diseases, cancers, and diabetes are increasingly prevalent, with socioeconomic disparities shaping access to care and outcomes.
4. CLINICAL FEATURES¶
Clinical manifestations vary by disease. HIV/AIDS presents with opportunistic infections and immune decline, while tuberculosis is characterized by chronic cough and weight loss. Malaria causes fever, chills, and anemia. NCDs like diabetes and cardiovascular disease present with metabolic and organ-specific symptoms.
4.1 HIV/AIDS¶
Progression from acute infection to AIDS is marked by CD4+ T-cell decline and opportunistic infections. Antiretroviral therapy (ART) suppresses viral load, but drug resistance and access remain challenges.
4.2 Tuberculosis¶
Classic symptoms include persistent cough, hemoptysis, and weight loss. Drug-resistant strains (MDR-TB, XDR-TB) require longer, more complex treatment regimens.
5. DIFFERENTIAL DIAGNOSIS¶
Differential diagnosis for infectious diseases includes malaria, tuberculosis, and HIV. For NCDs, conditions like diabetes and cardiovascular disease must be distinguished from other metabolic disorders. Environmental exposures and socioeconomic factors must be considered in all cases.
6. INVESTIGATIONS & DIAGNOSIS¶
Diagnostic approaches include laboratory tests (e.g., HIV PCR, TB sputum smear), imaging (e.g., chest X-ray for TB), and epidemiological data. The GBD study uses DALYs to quantify disease burden. Rapid diagnostic tests and molecular methods (e.g., PCR) improve detection of infectious diseases.
6.1 HIV Diagnosis¶
Confirmatory testing via ELISA and Western blot. Point-of-care rapid tests are used in resource-limited settings.
6.2 Tuberculosis Diagnosis¶
Sputum smear microscopy, nucleic acid amplification tests (NAAT), and chest imaging. GeneXpert MTB/RIF detects TB and resistance to rifampin.
7. MANAGEMENT & TREATMENT¶
Treatment strategies include ART for HIV, multidrug regimens for TB, and vector control for malaria. NCDs require lifestyle modifications, pharmacotherapy, and chronic care models. Global initiatives like the Global Fund and PEPFAR support treatment scale-up.
Table 485-2: Leading Causes of Death Worldwide, 2019¶
| DISEASE OR INJURY | DEATHS (MILLIONS) | PERCENTAGE OF TOTAL DEATHS |
|---|---|---|
| Ischemic heart disease | 9.1 | 16.1 |
| Stroke | 6.6 | 11.7 |
| COPD | 3.3 | 5.8 |
| Lower respiratory infection | 2.5 | 4.4 |
| Lung cancer | 2.0 | 3.6 |
| Neonatal disorders | 1.9 | 3.3 |
| Alzheimer’s disease | 1.6 | 2.9 |
| Diabetes | 1.6 | 2.7 |
| Diarrheal diseases | 1.5 | 2.7 |
| Cirrhosis | 1.5 | 2.6 |
7.1 HIV Treatment¶
ART regimens (e.g., tenofovir + lamivudine + efavirenz) reduce viral load and prevent transmission. The 90-90-90 targets aim for 90% of people living with HIV to know their status, be on ART, and achieve viral suppression.
7.2 Tuberculosis Treatment¶
Standardized regimens (e.g., isoniazid, rifampin, pyrazinamide) for drug-susceptible TB. DOTS-Plus addresses drug-resistant strains with expanded diagnostics and second-line drugs.
8. PROGNOSIS & COMPLICATIONS¶
Prognosis varies by disease. HIV with effective ART can achieve near-normal life expectancy. TB mortality declines with treatment adherence, but drug resistance worsens outcomes. NCDs like diabetes and cardiovascular disease lead to long-term complications and increased mortality.
8.1 HIV Prognosis¶
ART significantly improves survival, but treatment interruptions and drug resistance can lead to disease progression. Opportunistic infections remain a major cause of mortality.
8.2 Tuberculosis Prognosis¶
Early diagnosis and adherence to treatment reduce mortality. MDR-TB and XDR-TB have higher fatality rates and require prolonged, more toxic regimens.
9. SPECIAL CONSIDERATIONS¶
Global health equity requires addressing disparities in resource allocation, access to care, and health worker training. Special attention is needed for vulnerable populations, including children, women, and marginalized communities. Environmental and socioeconomic factors must be integrated into treatment planning.
9.1 Poverty and Health¶
Poverty exacerbates disease burden through limited access to clean water, sanitation, and healthcare. It also increases vulnerability to infectious diseases and reduces adherence to chronic disease management.
9.2 Health Workforce¶
Global health systems face shortages of trained personnel, particularly in low-income countries. Strengthening health workforce capacity is critical for achieving health equity.
10. KEY POINTS & CLINICAL PEARLS¶
Global health equity requires integrated approaches to prevention, care, and resource allocation. The rise of NCDs necessitates public health strategies targeting lifestyle and environmental risk factors. Effective treatment of HIV, TB, and malaria remains a priority, with emphasis on equitable access and drug resistance management.